News headlines about Catalyst Biosciences (NASDAQ:CBIO) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalyst Biosciences earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.524517225046 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern’s scoring:
- Catalyst Biosciences Announces Closing of Public Offering of … – GlobeNewswire (press release) (globenewswire.com)
- Catalyst Biosciences Inc (CBIO) Receives Average Rating of “Strong Buy” from Brokerages (americanbankingnews.com)
- Catalyst Biosciences Inc (CBIO) to Post FY2017 Earnings of ($7.85) Per Share, B. Riley Forecasts (americanbankingnews.com)
- Catalyst Biosciences Inc Expected to Earn FY2022 Earnings of $2.70 Per Share (CBIO) (americanbankingnews.com)
- Catalyst Biosciences Inc: This Analyst Even More Confident in Hemophilia B Asset Following Encouraging Phase II Data (smarteranalyst.com)
CBIO has been the subject of several analyst reports. Zacks Investment Research upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research report on Wednesday, November 8th. B. Riley began coverage on Catalyst Biosciences in a research report on Friday, December 8th. They issued a “buy” rating and a $19.00 price objective for the company. ValuEngine upgraded Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Chardan Capital boosted their price objective on Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $37.50.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.